Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
- Market Cap ₹ 5,283 Cr.
- Current Price ₹ 1,214
- High / Low ₹ 1,584 / 1,009
- Stock P/E 90.1
- Book Value ₹ 379
- Dividend Yield 0.00 %
- ROCE 4.56 %
- ROE 3.58 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 107% CAGR over last 5 years
- Debtor days have improved from 124 to 89.2 days.
Cons
- Stock is trading at 3.20 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.67.3 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
56 | 105 | 137 | 178 | 318 | 409 | |
73 | 137 | 191 | 222 | 353 | 439 | |
Operating Profit | -17 | -32 | -54 | -44 | -34 | -30 |
OPM % | -30% | -30% | -39% | -25% | -11% | -7% |
21 | 23 | 27 | 53 | 90 | 67 | |
Interest | 1 | 2 | 5 | 11 | 22 | 2 |
Depreciation | 4 | 7 | 9 | 10 | 9 | 9 |
Profit before tax | -2 | -18 | -41 | -12 | 24 | 27 |
Tax % | 0% | 0% | 0% | 0% | -58% | 28% |
-2 | -18 | -41 | -12 | 38 | 19 | |
EPS in Rs | -162.67 | -1,811.38 | -106.10 | -30.31 | 8.84 | 4.41 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 49% |
3 Years: | 44% |
TTM: | 28% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 107% |
3 Years: | 51% |
TTM: | 53% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 17% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 |
Reserves | -13 | -31 | -72 | -84 | 1,583 | 1,607 |
457 | 540 | 674 | 775 | 18 | 14 | |
21 | 23 | 47 | 68 | 125 | 139 | |
Total Liabilities | 466 | 533 | 654 | 764 | 1,769 | 1,804 |
46 | 50 | 51 | 41 | 34 | 29 | |
CWIP | 2 | 2 | 0 | 0 | 0 | 0 |
Investments | 38 | 39 | 39 | 41 | 41 | 277 |
380 | 442 | 563 | 682 | 1,694 | 1,498 | |
Total Assets | 466 | 533 | 654 | 764 | 1,769 | 1,804 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
-52 | -68 | -45 | -57 | -76 | -109 | |
-167 | -7 | -69 | -58 | -763 | 208 | |
178 | 76 | 127 | 91 | 926 | -41 | |
Net Cash Flow | -41 | 0 | 14 | -24 | 87 | 58 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 114 | 107 | 139 | 153 | 130 | 89 |
Inventory Days | 206 | 177 | 103 | 68 | 65 | 110 |
Days Payable | 101 | 48 | 99 | 132 | 88 | 87 |
Cash Conversion Cycle | 219 | 236 | 143 | 89 | 107 | 112 |
Working Capital Days | 2,022 | 1,210 | 1,123 | 1,086 | 855 | 459 |
ROCE % | -3% | -6% | -0% | 4% | 5% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 4 Jun
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report submitted for FY ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - Submission of Newspaper for publication of Audited Financial Results for the quarter and year ended March 31, 2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 May - Audio recording of Q4 FY25 earnings call uploaded on company website.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
27 May - Investor presentation on Audited Financial Results of the Company for the quarter and year ended March 31, 2025.
Concalls
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Mar 2024Transcript PPT
Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.